

## Biomarkers : An Important Strategy for Human Health Risk Assessment

PETER P. FU, \*YUH SHEN WU, \*JENG-SHIOW LAI,  
\*MEI IN CHUNG AND \*CHING-CHENG LAI

*National Center for Toxicological Research, Jefferson, Arkansas 72079, U.S.A.*

*\* Institute of Applied Chemistry, Providence University, Shalu, Taichung, Taiwan, ROC.*

### INTRODUCTION

Cancer epidemiologists estimates that as much as 90% of all cancer in humans is largely associated with our life style, i. e., diet and social habits<sup>(1,2)</sup>. It is believed that 80 to 90% of human cancer is preventable. Tobacco smoking accounts for approximately 30% of cancer deaths. The remaining 70% of cancer deaths is mainly due to the carcinogenic chemicals present in diet, drugs, cosmetics, and in the environment<sup>(3,4)</sup>. Therefore, it is important to determine the carcinogenic components that we expose to, so that we can avoid or reduce their intake.

Because most of the carcinogenic chemicals require metabolic activation, risk evaluation must be based on the quantitative estimate of the dose of the reactive metabolites delivered to the target tissues, and based on the carcinogenic potency of the metabolites. Thus, to perform risk assessment is highly challenging. Isolation, identification and quantification of toxic chemicals that we expose to are not easy. Accurate assessment of carcinogenic potency of a chemical is not easy either. Furthermore, production of tumors in an animal species does not prove that the chemical is a human carcinogen. Also, failure to produce tumors in experimental animals does not eliminate the possibility that the chemical would be carcinogenic in man. For animal tumorigenicity assay, tumorigenic potency of a chemical is species dependent, and strain dependent. Tumorigenic potency is also dependent on the route of administration, and other factors. In a word, there are a large number of

uncertainties concerning the extrapolation of experimental animal data for interpretation of human health risk posed by carcinogenic chemicals. Uncertainties are introduced in all the four steps for performing risk assessment. They are: (i) hazard identification; (ii) exposure assessment; (iii) dose-response assessment; and (iv) risk characterization.

Regulatory agencies, such as FDA and EPA, must assess human health risks posed by exposure to carcinogenic chemicals in order to make regulatory decisions that protect public health. However, because of a lack of understanding of the underlying biological, chemical, and physical processes which determine exposures and effects, the regulatory agencies are limited in the ability to assess health risks quantitatively. Without sufficient knowledge, uncertainties (assumptions) are introduced into the risk assessment process that allows wide interpretation of the limited experimental data that are available. As a consequence, it is important to pursue critical data on the relationship between exposure, dose to target tissue (delivered dose), and associated health effects. Emphasis is on the laboratory and field research to improve understanding of basic biological mechanisms, especially as they relate to our ability to extrapolate from one set of circumstances to another and will allow us to quantify the human health risks associated with human exposures.

In order to efficiently assess the human health risk posed by carcinogenic chemicals, a research strategy, biomarkers, has been recently pursued. This new approach can provide highly sensitive bioassays, and the

biological responses occurring in experimental animals can be potentially applied to humans.

### TYPES OF BIOMARKERS

The research on biomarkers is to provide new and potentially useful human biological markers as practical bioassays for risk assessment. Biomarkers are indicators of variation in cellular or physiological components or processes, structures, or functions that are measurable in a biological system or sample. A variety of parameters can be utilized as biomarkers. These at least include: metabolizing enzymes, metabolism patterns, parent carcinogenic substrate in target tissue, mutagenicity in urine, metabolite(s), protein adducts, and DNA adducts. There are mainly three types of biomarkers. They are: (i) biomarkers of exposure; (ii) biomarkers of susceptibility; and (iii) biomarkers of effect.

#### *Biomarkers of Exposure*

Biomarkers of exposure are the surrogates to determine the absorbed dose and the delivered (or target) dose of a chemical in the animal and human body. Biomarkers of exposure will be used as essential tools in monitoring and controlling exposure to a broad range of contaminants. For example, genotoxic solvents represent some of the most extensively used chemicals in industry, in research institutes, and even sometimes at home. Exposure to hazardous solvents can cause long-term genetic damage. Benzene, a leukemogen<sup>(5)</sup>, is a widespread genotoxic environmental contaminant and in some cases is also present in the cosmetics and drinking water. Benzene is regulated under the Clean Air Act posed by U. S. EPA. The dose-response relationship between human exposure to benzene and the development of toxic responses has not been fully established. Metabolism of benzene by humans and rodents results in the reactive intermediate, benzene oxide, that binds to in albumin to form the cysteine adduct s-phenylcysteine. This s-phenylcysteine adduct in albumin has been considered as an effective biological marker for exposure to benzene. Another example is aflatoxin B<sub>1</sub> (AFB<sub>1</sub>), which is a major food contaminant and is the agent sus-


pected to cause hepatocarcinoma in humans. Metabolism of AFB<sub>1</sub> yields AFB<sub>1</sub> 8,9-oxide and AFB<sub>1</sub> 8,9-dihydrodiol. Covalent binding of AFB<sub>1</sub> 8,9-oxide results in the formation of the corresponding DNA adduct. On the other hand, binding of AFB<sub>1</sub> 8,9-dihydrodiol with human serum albumin to yield protein adducts has been reported<sup>(6,7)</sup>. Both these DNA and protein adducts of AFB<sub>1</sub> have been utilized as biomarkers of AFB<sub>1</sub> exposure.

#### *Biomarkers of Susceptibility*

Carcinogenic compounds require metabolic activation in order to exert their biological activities, including carcinogenicity. It is known that the relative quantity of the metabolizing enzymes, such as the cytochrome p-450 isozymes, in humans and in experimental animals can be different. Thus, the metabolism rate of metabolic activation as well as detoxification of a chemical carcinogen can be considerably different from person to person, resulting in the differences in the susceptibility of carcinogen exposure. As a consequence, Differences in metabolizing enzymes can be useful biomarkers of susceptibility. For example, it is known that there are two distinct types of human acetyltransferases, the fast and the slow acetylator phenotypes<sup>(9-11)</sup>. A positive correlation has been found that, when exposed to aromatic amines, persons who have a slow acetylator phenotype encounter with a higher bladder cancer incidence than those with a fast acetylator phenotype<sup>(8)</sup>. On the other hand, persons with a fast acetylator phenotype have a higher tumor incidence than those with a slow acetylator phenotype<sup>(9,10)</sup>. Evidently, acetyltransferase is a biomarker of susceptibility for assessment of human health risk.

#### *Biomarkers of Effect*

It has been well supported by the experimental results that tumors induced by chemical carcinogens involve cytogenetic changes. Thus, if a carcinogen exerts its carcinogenic effect via a genetic mechanism, its DNA adduct can be a potential biomarker of effect. For example, AFB<sub>1</sub> DNA adduct has also been employed as a biomarker of effect of AFB<sub>1</sub>. However, not all the



carcinogen-modified DNA adducts can be used as biomarkers of effect. A representative example is 2-acetylaminofluorene (2-AAF). Upon metabolic activation of 2-AAF, reaction of cellular DNA with the resulted reactive metabolite, N-hydroxy-2-acetylaminofluorene generates three DNA adducts. They are: N-(deoxyguanosin-8-yl)-2-aminofluorene (dG-C8-AF), N-(deoxyguanosin-8-yl)-2-AAF (dG-C8-AAF), and 3-(deoxyguanosin-N<sup>2</sup>-yl)-2-AAF (dG-N<sup>2</sup>-AAF). Because of the bulky N-acetyl group, dG-C8-AAF distorts the DNA double helix significantly, and thus, is readily recognized by the DNA repair enzymes and is readily repaired. Its formation does not correlate with tumor induction and cannot be employed as a biomarker of effect of 2-AAF. The adduct dG-N<sup>2</sup>-AAF is not repaired and its quantity increases with extension of exposure time. However, dG-C8-AF is the only DNA adduct that has a half-life long enough to be detected in rat liver 2-3 weeks after feeding with 2-AAF. Therefore, dG-C8-AF can be a biomarker of effect of 2-AAF<sup>(11)</sup>. Another example is benzo [a] pyrene (BaP), which is the prototype for studying the chemical carcinogenesis of polycyclic aromatic hydrocarbons (PAHs), a class of genotoxic contaminants detected in the environment and in the food chain. Metabolism of BaP, generates BaP *trans*-7, 8-diol- *anti*-9, 10-epoxide as the ultimate metabolite. Reaction of this ultimate metabolite with DNA, both *in vitro* and *in vivo*, results in the formation of 10-(deoxyguanosin-N<sup>2</sup>-yl)-7, 8, 9-trihydroxy-7, 8, 9, 10-tetrahydrobenzo [a] pyrene as the major DNA adduct. This DNA adduct has been used as biomarkers of exposure, susceptibility and effect<sup>(12-14)</sup>.

### PROTEIN ADDUCTS AS BIOMARKERS

Covalent binding of chemical carcinogens to proteins can potentially reveal precise information about exposure of the carcinogens. Consequently, protein adducts are ideal biomarkers for risk assessment. Because tumors arise from cells that undergone a permanent heritable change in their genetic material, binding of the chemical carcinogens with cellular DNA in the

target tissues leading to the DNA is the critical step in the tumor formation. On the other hand, because protein is not the genetic material leading to tumor formation, protein adducts cannot be employed as biomarkers of effect. Nevertheless, if a relationship between the quantitative formation of protein adduct and the corresponding DNA adduct derived from the same chemical carcinogen can be established, this protein adduct can serve as a surrogate for DNA adduct, and thus can be a suitable biomarker of effect of this chemical carcinogen. An excellent review entitled "Protein adducts in the molecular dosimetry of chemical carcinogens" has recently been published by Skipper and Tannenbaum<sup>(15)</sup>. A number of carcinogen-protein adducts have been prepared. A high degree of specificity is characteristic of the interactions between the activated forms of chemical carcinogens and proteins<sup>(15)</sup>. As described in the review<sup>(15)</sup>, a good protein adduct used as a biomarker should at least include the following: (i) the adduct is chemically stable; (ii) the adduct does not influence the stability of protein; (iii) the adduct is accessible for epidemiological studies; and (iv) a relationship between the protein dose and DNA dose can be made. Both the hemoglobin and serum albumin adducts can meet all these criteria. Ehrenberg et al<sup>(16)</sup> reported the protein adduct of ethylene oxide in 1974 and this study represents the first report in the recognition of the potential of protein adducts to serve as surrogates for DNA adducts. Since then, a number of hemoglobin adducts and serum albumin adducts have been prepared. These include those derived from methyl methanesulfonate<sup>(17)</sup>, aflatoxin B<sub>1</sub><sup>(6,7)</sup>, fluoranthene<sup>(18)</sup>, 4-aminobiphenyl<sup>(19)</sup>, N-nitrosomelicotine<sup>(20)</sup>, styrene and styrene 7, 8-oxide<sup>(21)</sup>, diethylnitrosamine<sup>(22)</sup>, Glu-p-1<sup>(23)</sup>, and benzo[a] pyrene<sup>(24)</sup>.

Protein adducts are usually characterized by high-resolution GC/MS<sup>(25)</sup> and immunoassay including radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA)<sup>(26)</sup>. A method involving removal of the protein moiety from the protein adduct followed with characterization of the remaining carcinogen moiety by GC/MS has also been developed<sup>(27)</sup>.



There exist problems concerning the use of protein adducts as biomarkers. Human hemoglobin adducts have a lifespan of 120 days, and serum albumin adducts have a half-life of 20-25 days. Thus, for risk assessment, quantitative analysis of protein adducts sometimes is difficult. It is important to develop a long-term, or even a lifetime protein dosimeter. Currently, in most cases, it is difficult to characterize protein adducts by any conventional analytical methods, including mass spectrometry. Thus, it is timely and important to develop more advanced methodologies for better characterization.

### DNA ADDUCTS AS BIOMARKERS

Because DNA adducts are formed from covalent binding of the activated metabolites of chemical carcinogens with DNA, DNA adducts can provide insight into the mechanism by which the carcinogens induce tumors. Therefore, DNA adducts can be considered the best dosimeters to provide an indication of the relative risk of tumor induction. Currently, DNA adducts derived from different classes of chemical carcinogens have been prepared<sup>(14)</sup>. These include those from PAHs<sup>(14, 28, 29)</sup>, arylamines<sup>(11)</sup>, aflatoxins<sup>(30)</sup>, nitrosamines<sup>(31)</sup>, and nitro-PAHs<sup>(32)</sup>.

While DNA adducts represent the most promising biomarkers for risk assessment, it requires highly sensitive analytical techniques for characterization and quantification. This is because the quantity of DNA adducts formed *in vivo* or *in vitro* is generally extremely small. DNA adduct levels in experimental animals administered with carcinogens are generally on the range of 10 - 100 pmoles/mg DNA, which is equivalent to 3 adducts per 10<sup>5</sup>- 10<sup>6</sup> nucleotides<sup>(14)</sup>. The DNA adduct level expected based on human exposure is about 0.1 - 1 pmol/mg DNA, which is 100 times less than that from experimental animals. Thus, even after exposure to carcinogens in substantial amount, only about one carcinogen-modified DNA adduct per 10<sup>6</sup> to 10<sup>8</sup> nucleotides is formed. Furthermore, DNA accounts for only about 0.1% of a cell by weight. Therefore, only 1 mg of DNA can be obtained from 1 g of tissue. Thus, assuming

a concentration of 1 pmol/mg DNA of DNA adduct is formed, only about 10 ng of DNA adduct will be obtained from 20 g of tissue. Clearly, this requires skillful techniques for separation of the adduct, and requires sophisticated methodology for identification and quantification of the DNA adducts.


Currently, there are three major techniques that are highly sensitive and can be utilized for efficient separation and quantification of DNA adducts. They are: (i) immunoassay; (ii) mass spectrometry; and (iii) <sup>32</sup>P-postlabelling.

### IMMUNOASSAY

In the immunoassay, the monoclonal and polyclonal antibodies are prepared by dealing the carcinogen-modified DNA or carcinogen-nucleoside adducts as immunogens. The antibodies prepared are then used to identify and quantify the specific DNA adducts by either employing the RIA assay or the ELISA assay. The sensitivity of ELISA assay is about one adduct per 10<sup>7</sup> nucleotides. Although RIA assay is less sensitive, both ELISA and RIA assays are sensitive for efficiently assaying human DNA samples. Immunoassay is relatively inexpensive, and many samples can be analyzed simultaneously. However, immunoassay has disadvantages. The antibody prepared for a particular immunogen (modified DNA adduct) sometimes may not be specific, and therefore, may respond to a broad spectrum of DNA adducts. This will hamper accurate quantification. Another problem is the requirement of sufficient amount of modified DNA adduct used as an immunogen to prepare the corresponding antibody. As a consequence, it requires chemical synthesis to prepare the modified DNA adduct in sufficient quantity.

### MASS SPECTROMETRY

For structural identification, carcinogen-modified DNA adducts are enzymatically digested into the corresponding nucleosides which are analyzed by high resolution mass spectrometry and proton nuclear magnetic resonance spectroscopy. Technology in mass spectrometry has recently been developed rapidly and has facilitated in



identification of DNA adducts in extremely small quantity. In general, volatility, thermal and chemical stability, sensitivity and resolution capability are the major elements concerning the capability in detecting and quantifying a DNA adduct. While volatility, thermal stability, and chemical stability are the intrinsic characters of a chemical (DNA adduct), sensitivity and resolution capability involve the quality of the mass spectrometer used and the type and the quantity of the chemicals (DNA adducts) subjected for study. The modern highly sensitive mass spectrometric techniques have made significant progress, and have been utilized to analyze the carcinogen-modified DNA adducts in human samples. The developed methodologies at least include: (i) pre-separation of the components from a mixture; GC/MS, HPLC/MS, capillary LC/MS, zone electrophoresis (CZE); (ii) ionization techniques, electron impact, positive ion chemical ionization, negative ion chemical ionization, fast atom bombardment (FAB); continuous flow fast atom bombardment (CF-FAB), electrospray ionization (ESI), collision induced dissociation (CID); (iii) derivatization of the DNA adducts for mass spectral measurement; and (iv) removal of the nuclear base from the DNA adduct by a chemical reaction and mass spectral analysis of the remaining carcinogen moiety. Thus, based on the necessity, the mass spectrometric techniques employed for measurement of a DNA adduct can include at least the following on-line separation-MS systems: Ms/MS, FAB/MS, CFFAB/MS, CZE-CFFAB/MS, CZE-ESI/MS, capillary LC-CFFAB/MS, and capillary LC-ESI/MS. Currently, mass spectrometric techniques can detect one adduct per  $10^8$  nucleosides, and has a potential up to one adduct per  $10^{11}$  nucleosides. Consequently, mass spectrometry has a potential for identification of low levels of DNA adducts in physiological samples.

### <sup>32</sup>P-POSTLABELING

<sup>32</sup>P-Postlabeling is the most recently developed highly sensitive technique used for identification of carcinogen-modified DNA adducts<sup>(33)</sup>. This method is highly

sensitive, can detect DNA adducts at a level of one carcinogen-modified adduct in  $10^{10}$  nucleotides<sup>(34,35)</sup>. Another advantage of this method is that radioactivity is introduced after sample is collected from an *in vivo* or an *in vitro* system. The process of this method involves: (i) DNA adduct is first digested with DNase II and micrococcal endonuclease to the corresponding 3'-monophosphate nucleotide; (ii) conversion of the 3'-monophosphate nucleotide with [<sup>32</sup>P]ATP catalyzed with polynucleotide kinase to the <sup>32</sup>P-labeled 3'5'-bisphosphate nucleotide; (iii) separation of the modified adducts and removal of the unmodified adducts by multidirectional thin-layer chromatography (TLC); and (iv) identification of the specific adduct by comparing the location (spot) with that of a standard, and quantification of the adduct by autoradiography<sup>(33-55)</sup>. If the DNA adduct is derived from a PAH, a so-called nuclease pl-mediated technique has been developed, which can efficiently enhance the detection sensitivity<sup>(34)</sup>. On the other hand, the n-butanol extraction technique can enhance the detection of DNA adducts derived from aromatic amines or nitro-PAHs<sup>(35)</sup>.

<sup>32</sup>P-Postlabeling technique is currently the most promising methodology for detection of DNA adducts at a low level. This method has now been widely employed. It can also be employed for detection of unknown DNA adducts. Nevertheless, this method also has its problems. While this method can identify an unknown adduct, quantification of an unknown adduct is impossible. Another problem is that multidirectional TLC is not efficient enough to separate DNA adducts from the samples containing many adducts.

### FUTURE PERSPECTIVES

Biomarkers are potential surrogates for human health risk assessment. It can also provide information concerning the mechanisms by which the toxic chemicals exert their adverse activities, including carcinogenicity, in humans. Biomarkers can monitor human exposure and effect of a toxic component present in the food chain, drugs, or in the environment. Thus, it is anticipated that development of sensitive biomarkers for


risk assessment will be one of the major research areas in medical science and in regulatory research. The ideal biomarkers to be developed should be non-invasive and interpretable in terms of human susceptibility to exposure or effect. DNA adducts will be the critical biomarkers to measure the effect of a carcinogenic chemical to human health. Currently, although several modern techniques have been successfully employed to identify and quantify DNA adducts, all encounter different types of problems. The most important problem is detection capability. It is important to improve the current analytical methodologies and to develop new methodologies for accurate detection and quantification of DNA adducts, protein adducts and other biomarkers.

## REFERENCES

1. Diet, Nutrition, and Cancer, National Academy press Washington, D.C. 1982.
2. Dietary Mutagens, Environ. Health Persp. 1986 Vol. 67.
3. Ames, B. N. 1983. Dietary carcinogenesis and anticarcinogens, oxygen radicals and degenerative diseases. *Science*. 221:1256-1264.
4. Searle, C. E. (ed.). 1984. Chemical Carcinogens Vol. 1 and Vol. 2. ACS Monograph 182. American Chemical Society. Washington, D.C.
5. Vigliani, E. C. 1976. Leukemia associated with benzene exposure. *Ann. N. Y. Acad. Sci.* 271: 134-151.
6. Sabbioni, G., Skipper, P. L., Buchi, G. and Tannenbaum, S.R. 1987. Isolation and characterization of the major serum albumin adduct formed by aflatoxin B<sub>1</sub> in vivo in rats. *Carcinogenesis*. 8:819-924.
7. Wild, C. P., Garner, R. C., Montesano, R. and Tursi, F. 1986. Aflatoxin B<sub>1</sub> binding to plasma albumin and liver DNA upon chronic administration to rats. *Carcinogenesis*. 7:853-858.
8. Weber, W.W. and Hein, D.W. 1985. N-Acetylation pharmacogenetics. *Pharmacol. Rev.* 37:25-79.
9. Lang, N. P., Chu, D. Z. J., Hunter, C. F., Kendall, D. C., Flammang, T. J. and Kadlubar, F. F. 1986. Role of aromatic amine acetyltransferase in human colorectal cancer. *Arch. Surg.* 121:1259-1261.
10. Ilett, K.F., David, B.M., Detchon, P., Castleden, W.M. and Kwa, R. 1987. Acetylation phenotype in colorectal carcinoma. *Cancer Res.* 47: 1466-1469.
11. Beland, F.A. and kadlubar, F. F. 1985. Formation and persistence of arylamine DNA adduct in vivo, *Environ. Health Persp.* 62:19-30.
12. Jeffrey, A. M., Weinstein, I. B., Jennette, K. W., Grzeskowiak, K., Nakaishi, K., Harvey, R. G., Autrup, H., and Harris, C. 1977. Structures of benzo[a]pyrene-nucleic acid adducts formed in human and bovine bronchial explants. *Nature (Lond.)* 269:348-350.
13. Stevens, C. W., Bouck, N., Burgess, J. A. and Fahl, W. E. 1985. Benzo[a]pyrene diol-epoxides: Different mutagenic efficiency in human and bacterial cells. *Mutation Res.* 152:5-14.
14. Beland, F. A. and Poirier, M. C. 1989. DNA adducts and carcinogenesis. In: *The Pathobiology of Neoplasia*. pp. 57-80. Sirica, A. E. (ed.), Plenum Publishing Corp.
15. Skipper, P.L. and Tannenbaum, S.R. 1990. Protein adducts in the molecular dosimetry of chemical carcinogens. *Carcinogenesis*. 11:507-518.
16. Ehrenberg, L., Hiesche, K.D., Osterman-Golkar, S. and Wennberg, I. 1974. Evaluation of the genetic risks of alkylating agents: tissue doses in the mouse from air contaminated with ethylene oxide. *Mutat. Res.* 24:83-103.
17. Segerback, D., Calleman, C.J., Ehrenberg, L., Lofroth, G. and Osterman-Golkar, S. 1978. Evaluation of genetic risks of alkylating agents. IV. Quantitative determination of alkylated amino acids in haemoglobin as a measure of the dose after treatment of mice with methyl methanesulfonate. *Mutat. Res.* 49:71-82.
18. Hutchins, D.A., Skipper, P.L., Naylor, S. and Tannenbaum, S.R. 1988. Isolation and characteri-

# Angle

- zation of the major fluoranthene hemoglobin adducts formed in vivo in the rat. *Cancer Res.* 48:4756-4761.
19. Green, L. C., Skipper, P. L., Turesky, R. J., Bryant, M.S. and Tannebaum, S.R. 1984. In vivo dosimetry of 4-aminobiphenyl in rats via a cysteine adduct in hemoglobin. *Cancer Res.* 44:4254-4259.
  20. Carmella, S.G. and Hecht, S.S. 1987. Formation of hemoglobin adducts upon treatment of F344 rats with the tobacco specific nitrosamines 4-(methylnitrosamino)-1-(2-pyridyl)-1-butanone and N-nitrosomocotine. *Cancer Res.* 47:2626-2630.
  21. Nordqvist, M.B., Lof, A., Osterman-Golkar, S. and Walles, S. A. S. 1985. Covalent binding of styrene and styrene-7, 8-oxide to plasma protein, hemoglobin and DNA in the mouse. *Chem. Biol. Interactions*, 55:63-73.
  22. Osterman-Golkar, S. and Bergmark, E. 1988. Alkylation of hemoglobin, plasma proteins and DNA in the mouse by diethylnitrosamine. *Carcinogenesis*. 9:1915-1917.
  23. Umemoto, A. Monden, Y., Tsuda, M., Grivas, S. and Sugimura, T. 1988. Oxidation of the 2-hydrocamine derivative of 2-amino-6-methyl-dipyrido-[1,2-a3',2'-d]imidazole (Glu-P-1) to its 2-nitroso form, an ultimate form reacting with hemoglobin thiol groups. *Biochem. Biophys. Res. Commu.* 151:1326-1331.
  24. Skipper, P.L., Naylor, S., Gan, L.S., Dya, B. W., pastorelli, R. and Tannenbaum, S.R. 1989. Origin of tetrahydrotetraols derived from human hemoglobin adducts of benzo[a]pyrene. *Chem. Res. Toxicol.* 2:280-281.
  25. Stillwell, W.G., Bryant, M.S. and Wishnok, J. S. 1987. GC/MS analysis of biologically important aromatic amines. *Biomed. Environ. Mass Spectrom.* 14:22-227.
  26. Wild, C.P., Chapot, B. and Montesano. R. 1988. High specific aflatoxin (AF) antibodies recognize antigenic epitopes on human serum albumin obtained from populations exposed to aflatoxin. *Proc. Am. Assoc. Cancer Res.* 29:1031.
  27. Ting, D., Smith, M. T., Doane-Setzer, P. and Rappaport, S.M. 1990. analysis of styrene wxide-globin adducts based upon reaction with Raney nickel. *Carcinognensis*. 11:755-760.
  28. Walker, V.E., MacNeela, J.P., Swenverg, J. A., Tvnnner, Jr. M.J. and Fennell, T.R. (1992), Molecular dosimetry of ethylene oxide: Formation and persistence of N-(2-hydroxyethyl) valine in hemoglobin following repeated proposure of rats and Micr. *Cancer Res.*, 52:4320-4327.
  29. Dipple, A., Moschel, R.C., and Bigger, C.A.H. 1984. Polynuclear aromatic carcinogens, In: "Chemical Carcinogens", Vol. 1 (C.E. Searle, ed. ). pp. 41-163, American Chemical Society. Washington, D.C.
  30. Dipple, A., Pigott, M.A., Agarwal, S.k., Yagi, H., Sayer, J.M. and Jerina, D.M. 1987. Opticaly active benzo[c]phenanthrene diol epoxides bind extensively to adenine in DNA. *Nature (Lond.)* . 327:535-536.
  31. Groopman, J.D., Croy, R.G. and Wogana, G.N. 1981. In vitro reactions of aflatoxin B<sub>1</sub>-adducted DNA. *Proc. Natl. Acad. Sci. USA.* 78: 5445-5449.
  32. Beranek, D.T., Weis, C.C. and Swenson, D.H. 1980. A comparative quantitative analysis of methylated and ethylated DNA using high pressure liquid chromatography. *Carcinogenesis*. 1:595-606.
  33. Fu, P.P. 1990. Metabolism of nitro-polycyclic aromatic hydrocarbons. *Drug Metab. Rev.* 22: 209-268.
  34. Gupta, R. C, Reddy, M. V., and Randerath, K. 1982. <sup>32</sup>P-postlabelling analysis of non-radioactive aromatic cacinogen-DNA adducts. *Carcinogenesis*. 3:1081-1092.
  35. Reddy, M. V. and Randerath, K. 1986. Nuclease PI-mediated enhancement of sensitivity of <sup>32</sup>P-postlabelling test for structrually diverse DNA adducts. *Carcinogenesis*. 7:1543-1551.
  36. Gupta, R.C. 1985. Enhanced sensitivity of <sup>32</sup>P-postlabelling analysis of aromatic carcinogen: DNA



biological responses occurring in experimental animals can be potentially applied to humans.